The International Myeloma Working Group (IMWG) has recently published further consensus criteria for defining disease response in myeloma. Since the original response criteria were set in 2006, newer, more sensitive methods can now quantify myeloma cells as low as 1 in a million. Published in the Lancet Oncology, the updated criteria identify responses beyond complete response…
Clinicopathological significance of p15 promoter hypermethylation in multiple myeloma: a meta-analysis. Wei B et al. Onco Targets Ther. 2016 Jul 1;9:4015-22. doi: 10.2147/OTT.S102733. eCollection 2016. RGS1 expression is associated with poor prognosis in multiple myeloma. Roh J et al. J Clin Pathol. 2016 Jul 21. pii: jclinpath-2016-203713. doi: 10.1136/jclinpath-2016-203713. [Epub ahead of print]. Diagnostic performances of M-protein tests according to the clinical presentations…
Rationale, application, and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Merlini G et al. Leukemia. 2016 Jul 15. doi: 10.1038/leu.2016.191. [Epub ahead of print]. Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance. Hogan JJ et al. Clin J Am Soc Nephrol. 2016 Jul 14. pii:…
A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.
Chari A et al. Cancer. 2016 Jul 19. doi: 10.1002/cncr.30174. [Epub ahead of print].
T cells expressing an anti-B-cell-maturation-antigen chimeric antigen receptor cause remissions of multiple myeloma.
Ali SA et al. Blood. 2016 Jul 13. pii: blood-2016-04-711903. [Epub ahead of print].
Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche. Colombo M et al. Oncotarget. 2016 Jul 24. doi: 10.18632/oncotarget.10820. [Epub ahead of print]. HLA polymorphism and risk of multiple myeloma. Beksac M et al. Leukemia. 2016 Jul 27. doi: 10.1038/leu.2016.199. [Epub ahead of print]. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs. Ito T et…
The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders. Citrin R et al. Expert Rev Hematol. 2016 Jul 22. [Epub ahead of print]. A new era of immune therapy in multiple myeloma. Tai YT et al. Blood. 2016 Jul 21;128(3):318-9. doi: 10.1182/blood-2016-06-719856. The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a “real-world” study: the Royal Marsden…
Spinal disease in myeloma: cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracing.
Malhotra K et al. BMC Cancer. 2016 Jul 11;16:444. doi: 10.1186/s12885-016-2495-7.
Assessment of Bone Fragility in Patients with Multiple Myeloma Using QCT-Based Finite Element Modelling. Campbell GM et al. J Bone Miner Res. 2016 Jul 25. doi: 10.1002/jbmr.2924. [Epub ahead of print]. Intracranial Involvement by Plasma Cell Neoplasms. Wilberger AC et al. Am J Clin Pathol. 2016 Jul 24. pii: aqw058. [Epub ahead of print]. Upper Gastrointestinal Bleeding Due to Amyloidosis in a Patient…
Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression. Jung SH et al. Ann Hematol. 2016 Jul 1. [Epub ahead of print]. Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma. Jantunen E et al. Expert Rev Hematol. 2016 Jul 15:1-10. [Epub ahead of print]. Peripheral blood stem cells collection…